Drug Treatments for Core Symptoms of Autism Spectrum Disorder: Unmet Needs and Future Directions

 

 Permissions and Reprints

Abstract

Pharmacological treatments for core symptoms of Autism Spectrum Disorder (ASD) are still lacking. The clinical heterogeneity observed in this population (e.g., differences in cognitive functioning or in autism symptom severity) should be taken into account when a new drug is tested. Stratifying this population according to its neurobiological substrate could significantly improve our knowledge regarding the most appropriate pharmacological treatment for individual needs. In this review, we discuss the possible genetic and biological pathways, including the Glutamatergic, GABAergic, and mTOR systems, involved in the pathophysiology of autism, as well as the mechanisms that may be targeted by new drug interventions. Finally, we describe the current progress from the preclinical and clinical studies on some potential therapeutic options for ASD core symptoms.

• References

• 1 American Psychiatric Association. Report of DSM-5 Proposed Criteria for Autism Spectrum Disorder. American Psychiatric Association 2013
  PubMedGoogle Scholar
• 2 Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 2014; 63: 1-21
  PubMedGoogle Scholar
• 3 Wing L, Potter D. The epidemiology of autistic spectrum disorders: is the prevalence rising?. Ment Retard Dev Disabil Res Rev 2002; 8 (03) 151-161
  CrossrefPubMedGoogle Scholar
• 4 Persico AM, Arango C, Buitelaar JK. , et al; European Child and Adolescent Clinical Psychopharmacology Network. Unmet needs in paediatric psychopharmacology: present scenario and future perspectives. Eur Neuropsychopharmacol 2015; 25 (10) 1513-1531
  CrossrefPubMedGoogle Scholar
• 5 Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 2008; 47 (08) 921-929
  CrossrefPubMedGoogle Scholar
• 6 Benvenuto A, Battan B, Porfirio MC, Curatolo P. Pharmacotherapy of autism spectrum disorders. Brain Dev 2013; 35 (02) 119-127
  CrossrefPubMedGoogle Scholar
• 7 Jobski K, Höfer J, Hoffmann F, Bachmann C. Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review. Acta Psychiatr Scand 2017; 135 (01) 8-28
  CrossrefPubMedGoogle Scholar
• 8 Mazzone L, Ruta L, Reale L. Psychiatric comorbidities in asperger syndrome and high functioning autism: diagnostic challenges. Ann Gen Psychiatry 2012; 11 (01) 16 . Doi: 10.1186/1744-859X-11-16
  CrossrefPubMedGoogle Scholar
• 9 Masi A, De Mayo MM, Glozier N, Guastella AJ. An overview of autism spectrum disorder, heterogeneity and treatment options. Neurosci Bull 2017 . Doi: 10.1007/s12264-017-0100-y
  PubMedGoogle Scholar
• 10 Scahill L, Aman MG, McDougle CJ. , et al. Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. J Autism Dev Disord 2009; 39 (05) 720-729
  CrossrefPubMedGoogle Scholar
• 11 McDougle CJ, Scahill L, McCracken JT. , et al. Research units on pediatric psychopharmacology (RUPP) autism network. Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 2000; 9 (01) 201-224
  CrossrefPubMedGoogle Scholar
• 12 Dove D, Warren Z, McPheeters ML, Taylor JL, Sathe NA, Veenstra-VanderWeele J. Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics 2012; 130 (04) 717-726
  CrossrefPubMedGoogle Scholar
• 13 Food and Drug Administration (FDA). FDA approves the first drug to treat irritability associated with autism, risperdal. 2006 . Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759.htm. Accessed February 26, 2016
  PubMedGoogle Scholar
• 14 Bristol-Myers Squibb. U.S. ood and drug administration approves ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients (Ages 6 to 17 Years). Available at: http://news.bms.com/press-release/rd-news/us-food-and-drug-administration-approves-abilify-aripiprazole-treatment-irrita . Accessed April 19, 2016
  PubMedGoogle Scholar
• 15 Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 2008; 172: 199-212
  PubMedGoogle Scholar
• 16 Gandal MJ, Leppa V, Won H, Parikshak NN, Geschwind DH. The road to precision psychiatry: translating genetics into disease mechanisms. Nat Neurosci 2016; 19 (11) 1397-1407
  CrossrefPubMedGoogle Scholar
• 17 Vorstman JA, Ophoff RA. Genetic causes of developmental disorders. Curr Opin Neurol 2013; 26 (02) 128-136
  CrossrefPubMedGoogle Scholar
• 18 Chahrour M, O'Roak BJ, Santini E, Samaco RC, Kleiman RJ, Manzini MC. Current perspectives in autism spectrum disorder: from genes to therapy. J Neurosci 2016; 36 (45) 11402-11410
  CrossrefPubMedGoogle Scholar
• 19 Monteiro P, Feng G. SHANK proteins: roles at the synapse and in autism spectrum disorder. Nat Rev Neurosci 2017; 18 (03) 147-157
  CrossrefPubMedGoogle Scholar
• 20 Durand CM, Perroy J, Loll F. , et al. SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol Psychiatry 2012; 17 (01) 71-84
  CrossrefPubMedGoogle Scholar
• 21 Mei Y, Monteiro P, Zhou Y. , et al. Adult restoration of Shank3 expression rescues selective autistic-like phenotypes. Nature 2016; 530 (7591): 481-484
  CrossrefPubMedGoogle Scholar
• 22 Yang M, Bozdagi O, Scattoni ML. , et al. Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice. J Neurosci 2012; 32 (19) 6525-6541
  CrossrefPubMedGoogle Scholar
• 23 Pizzarelli R, Cherubini E. Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast 2011; 2011: 297153 . Doi: 10.1155/2011/297153
  PubMedGoogle Scholar
• 24 Uzunova G, Pallanti S, Hollander E. Excitatory/inhibitory imbalance in autism spectrum disorders: Implications for interventions and therapeutics. World J Biol Psychiatry 2016; 17 (03) 174-186
  CrossrefPubMedGoogle Scholar
• 25 Coghlan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ. GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev 2012; 36 (09) 2044-2055
  CrossrefPubMedGoogle Scholar
• 26 Port RG, Gaetz W, Bloy L. , et al. Exploring the relationship between cortical GABA concentrations, auditory gamma-band responses and development in ASD: Evidence for an altered maturational trajectory in ASD. Autism Res 2016 . Doi: 10.1002/aur.1686
  PubMedGoogle Scholar
• 27 Fatemi SH, Reutiman TJ, Folsom TD, Rustan OG, Rooney RJ, Thuras PD. Downregulation of GABAA receptor protein subunits α6, β2, δ, ε, γ2, θ, and ρ2 in superior frontal cortex of subjects with autism. J Autism Dev Disord 2014; 44 (08) 1833-1845
  CrossrefPubMedGoogle Scholar
• 28 Brooks-Kayal A. Epilepsy and autism spectrum disorders: are there common developmental mechanisms?. Brain Dev 2010; 32 (09) 731-738
  CrossrefPubMedGoogle Scholar
• 29 Buckley AW, Holmes GL. Epilepsy and autism. Cold Spring Harb Perspect Med 2016; 6 (04) a022749 . Doi: 10.1101/cshperspect.a022749
  CrossrefPubMedGoogle Scholar
• 30 Persico M, Di Dato A, Orteca N, Cimino P, Novellino E, Fattorusso C. Use of integrated computational approaches in the search for new therapeutic agents. Mol Inform 2016; 35 (8-9): 309-325
  CrossrefPubMedGoogle Scholar
• 31 Jacquemont S, Berry-Kravis E, Hagerman R. , et al. The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231 (06) 1237-1250
  CrossrefPubMedGoogle Scholar
• 32 Geschwind DH. Genetics of autism spectrum disorders. Trends Cogn Sci 2011; 15 (09) 409-416
  CrossrefPubMedGoogle Scholar
• 33 Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 2015; 14 (07) 733-745
  CrossrefPubMedGoogle Scholar
• 34 Zhou J, Parada LF. PTEN signaling in autism spectrum disorders. Curr Opin Neurobiol 2012; 22 (05) 873-879
  CrossrefPubMedGoogle Scholar
• 35 Walsh KS, Vélez JI, Kardel PG. , et al. Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Dev Med Child Neurol 2013; 55 (02) 131-138
  CrossrefPubMedGoogle Scholar
• 36 Ehninger D. From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches. Neuropharmacology 2013; 68: 97-105
  CrossrefPubMedGoogle Scholar
• 37 Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 2011; 480 (7375): 63-68
  CrossrefPubMedGoogle Scholar
• 38 Wenger TL, Kao C, McDonald-McGinn DM. , et al. The role of mGluR copy number variation in genetic and environmental forms of syndromic autism spectrum disorder. Sci Rep 2016; 6: 19372 . Doi: 10.1038/srep19372
  CrossrefPubMedGoogle Scholar
• 39 Ehninger D, Han S, Shilyansky C. , et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 2008; 14 (08) 843-848
  CrossrefPubMedGoogle Scholar
• 40 Powell EM, Campbell DB, Stanwood GD, Davis C, Noebels JL, Levitt P. Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J Neurosci 2003; 23 (02) 622-631
  CrossrefPubMedGoogle Scholar
• 41 Curatolo P, Napolioni V, Moavero R. Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment. J Child Neurol 2010; 25 (07) 873-880
  CrossrefPubMedGoogle Scholar
• 42 Lozano R, Azarang A, Wilaisakditipakorn T, Hagerman RJ. Fragile X syndrome: a review of clinical management. Intractable Rare Dis Res 2016; 5 (03) 145-157
  CrossrefPubMedGoogle Scholar
• 43 Bagni C, Oostra BA. Fragile X syndrome: from protein function to therapy. Am J Med Genet A 2013; 161A (11) 2809-2821
  PubMedGoogle Scholar
• 44 Bardoni B, Capovilla M, Lalli E. Modeling Fragile X syndrome in neurogenesis: an unexpected phenotype and a novel tool for future therapies. Neurogenesis (Austin) 2017; 4 (01) e1270384 . Doi: 10.1080/23262133.2016.1270384
  CrossrefPubMedGoogle Scholar
• 45 Guo W, Polich ED, Su J. , et al. Fragile X Proteins FMRP and FXR2P control synaptic GluA1 expression and neuronal maturation via distinct mechanisms. Cell Reports 2015; 11 (10) 1651-1666
  CrossrefPubMedGoogle Scholar
• 46 Sato A. mTOR, a potential target to treat autism spectrum disorder. CNS Neurol Disord Drug Targets 2016; 15 (05) 533-543
  CrossrefPubMedGoogle Scholar
• 47 Bernardet M, Crusio WE. Fmr1 KO mice as a possible model of autistic features. Sci World J 2006; 6: 1164-1176
  CrossrefPubMedGoogle Scholar
• 48 Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 2002; 99 (11) 7746-7750
  CrossrefPubMedGoogle Scholar
• 49 Canitano R. New experimental treatments for core social domain in autism spectrum disorders. Front Pediatr 2014; 2: 61 . Doi: 10.3389/fped.2014.00061
  PubMedGoogle Scholar
• 50 Burket JA, Herndon AL, Winebarger EE, Jacome LF, Deutsch SI. Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: possible implications for the pharmacotherapy of autism spectrum disorders. Brain Res Bull 2011; 86 (3-4): 152-158
  CrossrefPubMedGoogle Scholar
• 51 Silverman JL, Pride MC, Hayes JE. , et al. GABAB receptor agonist R-Baclofen reverses social deficits and reduces repetitive behavior in two mouse models of autism. Neuropsychopharmacology 2015; 40 (09) 2228-2239
  CrossrefPubMedGoogle Scholar
• 52 Silverman JL, Oliver CF, Karras MN, Gastrell PT, Crawley JN. Ampakine enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology 2013; 64: 268-282
  CrossrefPubMedGoogle Scholar
• 53 Veenstra-VanderWeele J, Cook EH, King BH. , et al. Arbaclofen in children and adolescents with autism spectrum disorder: A randomized, controlled, phase 2 trial. Neuropsychopharmacology 2016 . Doi: 10.1038/npp.2016.237
  PubMedGoogle Scholar
• 54 Hollander E, Uzunova G. Are there new advances in the pharmacotherapy of autism spectrum disorders?. World Psychiatry 2017; 16 (01) 101-102
  CrossrefPubMedGoogle Scholar
• 55 Hosenbocus S, Chahal R. Memantine: a review of possible uses in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2013; 22 (02) 166-171
  PubMedGoogle Scholar
• 56 Ghaleiha A, Asadabadi M, Mohammadi MR. , et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2013; 16 (04) 783-789
  CrossrefPubMedGoogle Scholar
• 57 Nikvarz N, Alaghband-Rad J, Tehrani-Doost M, Alimadadi A, Ghaeli P. Comparing efficacy and side effects of memantine vs. risperidone in the treatment of autistic disorder. Pharmacopsychiatry 2017; 50 (01) 19-25
  Article in Thieme ConnectPubMedGoogle Scholar
• 58 Aman MG, Findling RL, Hardan AY. , et al. Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension. J Child Adolesc Psychopharmacol 2016 . Doi: 10.1089/cap.2015.0146
  PubMedGoogle Scholar
• 59 Cheh MA, Millonig JH, Roselli LM. , et al. En2 knockout mice display neurobehavioral and neurochemical alterations relevant to autism spectrum disorder. Brain Res 2006; 1116 (01) 166-176
  CrossrefPubMedGoogle Scholar
• 60 Benayed R, Choi J, Matteson PG. , et al. Autism-associated haplotype affects the regulation of the homeobox gene, ENGRAILED 2. Biol Psychiatry 2009; 66 (10) 911-917
  CrossrefPubMedGoogle Scholar
• 61 Provenzano G, Clementi E, Genovesi S. , et al. GH dysfunction in Engrailed-2 knockout mice, a model for autism spectrum disorders. Front Pediatr 2014; 2: 92 . Doi: 10.3389/fped.2014.00092
  PubMedGoogle Scholar
• 62 Berry-Kravis EM, Hessl D, Rathmell B. , et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012; 4 (152) 152ra127 . Doi: 10.1126/scitranslmed.3004214
  PubMedGoogle Scholar
• 63 Erickson CA, Veenstra-Vanderweele JM, Melmed RD. , et al. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord 2014; 44 (04) 958-964
  CrossrefPubMedGoogle Scholar
• 64 Napolioni V, Moavero R, Curatolo P. Recent advances in neurobiology of tuberous sclerosis complex. Brain Dev 2009; 31 (02) 104-113
  CrossrefPubMedGoogle Scholar
• 65 Kilincaslan A, Kok BE, Tekturk P, Yalcinkaya C, Ozkara C, Yapici Z. Beneficial effects of everolimus on autism and attention-deficit/hyperactivity disorder symptoms in a group of patients with tuberous sclerosis complex. J Child Adolesc Psychopharmacol 2016 . Doi: 10.1089/cap.2016.0100
  PubMedGoogle Scholar
• 66 Franz DN, Belousova E, Sparagana S. , et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381 (9861): 125-132
  CrossrefPubMedGoogle Scholar
• 67 Bissler JJ, Kingswood JC, Radzikowska E. , et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381 (9869): 817-824
  CrossrefPubMedGoogle Scholar
• 68 French JA, Lawson JA, Yapici Z. , et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388 (10056): 2153-2163
  CrossrefPubMedGoogle Scholar
• 69 Talos DM, Sun H, Zhou X. , et al. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS One 2012; 7 (05) e35885 . Doi: 10.1371/journal.pone.0035885
  CrossrefPubMedGoogle Scholar
• 70 Guastella AJ, Gray KM, Rinehart NJ. , et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. J Child Psychol Psychiatry 2015; 56 (04) 444-452
  CrossrefPubMedGoogle Scholar
• 71 Yatawara CJ, Einfeld SL, Hickie IB, Davenport TA, Guastella AJ. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry 2016; 21 (09) 1225-1231
  CrossrefPubMedGoogle Scholar
• 72 Bethlehem RAI, Baron-Cohen S, van Honk J, Auyeung B, Bos PA. The oxytocin paradox. Front Behav Neurosci 2014; 8: 48 . Doi: 10.3389/fnbeh.2014.00048
  PubMedGoogle Scholar
• 73 Ross HE, Young LJ. Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior. Front Neuroendocrinol 2009; 30 (04) 534-547
  CrossrefPubMedGoogle Scholar
• 74 Bethlehem RA, van Honk J, Auyeung B, Baron-Cohen S. Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies. Psychoneuroendocrinology 2013; 38 (07) 962-974
  CrossrefPubMedGoogle Scholar
• 75 Dadds MR, MacDonald E, Cauchi A, Williams K, Levy F, Brennan J. Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. J Autism Dev Disord 2014; 44 (03) 521-531
  CrossrefPubMedGoogle Scholar
• 76 Husarova VM, Lakatosova S, Pivovarciova A. , et al. Plasma oxytocin in children with autism and its correlations with behavioral parameters in children and parents. Psychiatry Investig 2016; 13 (02) 174-183
  CrossrefPubMedGoogle Scholar
• 77 Di Napoli A, Warrier V, Baron-Cohen S, Chakrabarti B. Genetic variation in the oxytocin receptor (OXTR) gene is associated with Asperger Syndrome. Mol Autism 2014; 5 (01) 48 . Doi: 10.1186/2040-2392-5-48
  CrossrefPubMedGoogle Scholar
• 78 Watanabe T, Otowa T, Abe O. , et al. Oxytocin receptor gene variations predict neural and behavioral response to oxytocin in autism. Soc Cogn Affect Neurosci 2017; 12 (03) 496-506
  CrossrefPubMedGoogle Scholar
• 79 Guastella AJ, Einfeld SL, Gray KM. , et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010; 67 (07) 692-694
  CrossrefPubMedGoogle Scholar
• 80 Anagnostou E, Soorya L, Chaplin W. , et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism 2012; 3 (01) 16 . Doi: 10.1186/2040-2392-3-16
  CrossrefPubMedGoogle Scholar
• 81 Domes G, Kumbier E, Heinrichs M, Herpertz SC. Oxytocin promotes facial emotion recognition and amygdala reactivity in adults with asperger syndrome. Neuropsychopharmacology 2014; 39 (03) 698-706
  CrossrefPubMedGoogle Scholar
• 82 Du L, Shan L, Wang B. , et al. A pilot study on the combination of applied behavior analysis and bumetanide treatment for children with autism. J Child Adolesc Psychopharmacol 2015; 25 (07) 585-588
  CrossrefPubMedGoogle Scholar
• 83 Tyzio R, Nardou R, Ferrari DC. , et al. Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. Science 2014; 343 (6171): 675-679
  CrossrefPubMedGoogle Scholar
• 84 Lemonnier E, Ben-Ari Y. The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. Acta Paediatr 2010; 99 (12) 1885-1888
  CrossrefPubMedGoogle Scholar
• 85 Lemonnier E, Degrez C, Phelep M. , et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2012; 2: e202 . Doi: 10.1038/tp.2012.124
  CrossrefPubMedGoogle Scholar
• 86 Steenweg-de Graaff J, Ghassabian A, Jaddoe VW, Tiemeier H, Roza SJ. Folate concentrations during pregnancy and autistic traits in the offspring. The generation R study. Eur J Public Health 2015; 25 (03) 431-433
  CrossrefPubMedGoogle Scholar
• 87 Shoffner J, Trommer B, Thurm A. , et al. CSF concentrations of 5-methyltetrahydrofolate in a cohort of young children with autism. Neurology 2016; 86 (24) 2258-2263
  CrossrefPubMedGoogle Scholar
• 88 Frye RE, Slattery J, Delhey L. , et al. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry 2016; 00: 1-10
  PubMedGoogle Scholar